Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.

1002Background: Abemaciclib is a selective inhibitor of CDK4 & 6 that is dosed on a continuous schedule and is approved for the treatment of HR+, HER2- advanced breast cancer (ABC) as monotherapy a...